Literature DB >> 9264408

The protooncogene product, PEBP2beta/CBFbeta, is mainly located in the cytoplasm and has an affinity with cytoskeletal structures.

Y Tanaka1, T Watanabe, N Chiba, M Niki, Y Kuroiwa, T Nishihira, S Satomi, Y Ito, M Satake.   

Abstract

The Pebpb2/Cbfb gene encodes the non-DNA binding beta subunit of the heterodimeric transcription factor, PEBP2/CBF, and has been implicated in a subtype of human acute myeloid leukemia, as well as being indispensable for the development of definitive hematopoiesis in the murine fetal liver. By examining a subcellular localization of the PEBP2beta/CBFbeta protein in tissue culture cells, we could reveal an additional aspect of the protein other than to be a subunit of a transcription factor. Immunoblot and immunocytochemical staining showed that PEBP2beta/CBFbeta was mostly present in the cytoplasm. This PEBP2beta/CBFbeta was free from its DNA-binding partner, the alpha subunit of PEBP2/CBF, as judged by the electrophoretic mobility shift assays. Furthermore, a significant amount of PEBP2beta/CBFbeta was retained in the cytoskeleton preparation after detergent extraction of the cells and was found by double immunofluorescence to colocalize with the F-actin on stress fibers and the vinculin in membrane processes. Thus, the present study extends PEBP2beta/CBFbeta to be a cytoskeleton-affinitive as well as nuclear protein. The implications of these results are discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9264408     DOI: 10.1038/sj.onc.1201235

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25).

Authors:  M Osaka; J D Rowley; N J Zeleznik-Le
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

2.  Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein.

Authors:  Tanawan Kummalue; Jianrong Lou; Alan D Friedman
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

3.  Filamin A-bound PEBP2beta/CBFbeta is retained in the cytoplasm and prevented from functioning as a partner of the Runx1 transcription factor.

Authors:  Naomi Yoshida; Takehiro Ogata; Kenji Tanabe; Songhua Li; Megumi Nakazato; Kazuyoshi Kohu; Toshiro Takafuta; Sandor Shapiro; Yasutaka Ohta; Masanobu Satake; Toshio Watanabe
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

4.  Involvement of actin microfilaments in the replication of human parainfluenza virus type 3.

Authors:  S Gupta; B P De; J A Drazba; A K Banerjee
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

5.  The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates.

Authors:  N Adya; T Stacy; N A Speck; P P Liu
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

6.  CBFβ and the leukemogenic fusion protein CBFβ-SMMHC associate with mitotic chromosomes to epigenetically regulate ribosomal genes.

Authors:  Cesar Lopez-Camacho; Andre J van Wijnen; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  J Cell Biochem       Date:  2014-12       Impact factor: 4.429

7.  Core binding factor β (CBFβ) is retained in the midbody during cytokinesis.

Authors:  Cesar Lopez-Camacho; Andre J van Wijnen; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2014-10       Impact factor: 6.384

8.  Integrative analysis of RUNX1 downstream pathways and target genes.

Authors:  Joëlle Michaud; Ken M Simpson; Robert Escher; Karine Buchet-Poyau; Tim Beissbarth; Catherine Carmichael; Matthew E Ritchie; Frédéric Schütz; Ping Cannon; Marjorie Liu; Xiaofeng Shen; Yoshiaki Ito; Wendy H Raskind; Marshall S Horwitz; Motomi Osato; David R Turner; Terence P Speed; Maria Kavallaris; Gordon K Smyth; Hamish S Scott
Journal:  BMC Genomics       Date:  2008-07-31       Impact factor: 3.969

9.  Dysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancer.

Authors:  C L Andersen; L L Christensen; K Thorsen; T Schepeler; F B Sørensen; H W Verspaget; R Simon; M Kruhøffer; L A Aaltonen; S Laurberg; T F Ørntoft
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

10.  The Runx1 transcription factor inhibits the differentiation of naive CD4+ T cells into the Th2 lineage by repressing GATA3 expression.

Authors:  Okiru Komine; Keitaro Hayashi; Waka Natsume; Toshio Watanabe; Youichi Seki; Noriyasu Seki; Ryoji Yagi; Wataru Sukzuki; Hidekazu Tamauchi; Katsuto Hozumi; Sonoko Habu; Masato Kubo; Masanobu Satake
Journal:  J Exp Med       Date:  2003-06-30       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.